Zobrazeno 1 - 10
of 41
pro vyhledávání: '"I Plasencia García"'
Autor:
A Martín López, MÁ Ocaña Gómez, P Joy Carmona, CL Díaz Díaz, J Esquivel Negrín, JA Montero Delgado, A Santos Fagundo, G Avanzini Martínez, FJ Merino Alonso, I Plasencia García, KI Álvarez Tosco
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::223f55a3efde38093e16a2cc1de34ffa
https://doi.org/10.1136/ejhpharm-2023-eahp.385
https://doi.org/10.1136/ejhpharm-2023-eahp.385
Autor:
J Merino Alonso, I Plasencia García, T Betancor García, E Tévar Alfonso, A Ferrer Machín, M Vera Cabrera, CL Diaz Diaz, I González García
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance The acquisition of resistance by bacteria has meant that new antimicrobials appear. Ceftazidime–avibactam is a restricted antibiotic that is used in multiresistant infections that put the patient‘s life at risk. Aim and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c10f89ff5d5b39e3d4b5ac62c1385f17
https://doi.org/10.1136/ejhpharm-2020-eahpconf.340
https://doi.org/10.1136/ejhpharm-2020-eahpconf.340
Autor:
L Díaz Díaz, J Merino Alonso, C Perez Martin, S Hernández Rojas, I González García, M Vera Cabrera, K Álvarez Tosco, T Betancor García, R Mesa Expósito, A Ferrer Machín, I Plasencia García
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Transplanted patients are at risk of developing post-transplant diabetes as a metabolic complication of immunosuppressive therapy, which results in greater therapeutic complexity. Aim and objectives To evaluate the percentag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58243398acc3e0934aff6fe2fe74af86
https://doi.org/10.1136/ejhpharm-2020-eahpconf.229
https://doi.org/10.1136/ejhpharm-2020-eahpconf.229
Autor:
I Plasencia García, L Díaz Díaz, I González García, C. Perez, A Ferrer Machín, J Merino Alonso, E Tévar Alfonso, MA Ocaña Gomez, K Álvarez Tosco, R Mesa Expósito, M Vera Cabrera
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The consequence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a hypotonic hyponatraemia. Urea is a well tolerated therapeutic option indicated to correct sodium levels, acting as an osmotic diure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6bd65f858f95e9eca361ec7e4f2efd5
https://doi.org/10.1136/ejhpharm-2020-eahpconf.119
https://doi.org/10.1136/ejhpharm-2020-eahpconf.119
Autor:
M Vera Cabrera, K Álvarez Tosco, MA Ocaña Gomez, JA Martin Conde, A. de León Gil, I Plasencia García, FJ Merino Alonso, C Perez Martin, R Mesa Expósito, E Tevar Alonso, A Ferrer Machín
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The problem of severe asthma refractory to treatment has been addressed in clinical practice guidelines but there is still a notable percentage of patients poorly controlled, under treated and with inadequate follow-up. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66bcb84821972966e33ef9fac8bbb1c5
https://doi.org/10.1136/ejhpharm-2020-eahpconf.246
https://doi.org/10.1136/ejhpharm-2020-eahpconf.246
Autor:
M Vera Cabrera, S Hernández Rojas, JA Morales Barrios, A Ferrer Machín, E Gómez Melini, I Plasencia García, J Merino Alonso
Publikováno v:
Eur J Hosp Pharm
Background Patients undergoing liver transplantation require pharmacological treatment indefinitely and some patients have complications related to this treatment (diabetes, high cholesterol, high blood pressure, impaired renal function, osteoporosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7618903a261ba99c0d80561a691bbbe7
https://europepmc.org/articles/PMC7535708/
https://europepmc.org/articles/PMC7535708/
Autor:
I Plasencia García, E Gómez Melini, JA Montero Delgado, JT de Pourcq, MM Viña Romero, FJ Merino Alonso, F Gutiérrez Nicolás, E Ramos Santana, Cantudo Cuenca, M Suarez Gonzalez, E Tévar Alfonso
Publikováno v:
Eur J Hosp Pharm
Background The number of medical apps has increased exponentially in recent years, with more than 2 30 000 available. Because of the lack of regulation, some of these apps may offer inaccurate content or may not reach the minimum quality standards in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e059fb01c45e4643b26ebce8053a79a
https://europepmc.org/articles/PMC7535738/
https://europepmc.org/articles/PMC7535738/
Autor:
P Olvera, M Suarez Gonzalez, E Tevar Alonso, FJ Merino Alonso, MA Ocaña Gomez, M Vera Cabrera, I Plasencia García, A Ferrer Machín, E Gómez Melini, JA Morales Barrios, R Mesa Expósito
Publikováno v:
Eur J Hosp Pharm
Background Diabetes is a chronic pathology of high prevalence and a large number of associated comorbidities that have an impact on patients’ quality of life. In the hospital environment, poor insulin adherence may lead to episodes of hyperglycaemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c53498467d3bc9c902bbdaf6d1bc14
https://europepmc.org/articles/PMC7535421/
https://europepmc.org/articles/PMC7535421/
Autor:
I Plasencia García, FJ Merino Alonso, A Montero Delgado, E Ramos Santana, JA Leon Gil, S Hernández Rojas, C Fraile Clemente, MA Navarro Dávila, A Ferrer Machín, M Vera Cabrera, K Viñas Romero
Publikováno v:
Eur J Hosp Pharm
Background Hazardous drugs (MPs) are defined as the drugs that cause carcinogenicity, teratogenicity, reproductive toxicity, low-dose organ toxicity, genotoxicity, and new drugs with structure profiles and toxicity similar to existing drugs that were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b6d137c7097a3289786507fdc67c8fc
https://doi.org/10.1136/ejhpharm-2018-eahpconf.455
https://doi.org/10.1136/ejhpharm-2018-eahpconf.455
Autor:
I Plasencia García, M Suarez Gonzalez, E Gómez Melini, E Ramos Santana, S Hernández Rojas, MA Ocaña Gomez, P Diaz Ruiz, J Merino Alonso
Publikováno v:
Eur J Hosp Pharm
Background Secukinumab is a monoclonal antibody designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A, whereas ustekinumab is also a monoclonal antibody which attaches to two cytokines called interleukin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb82c7cbb1785b38956381db4a8a3fb
https://doi.org/10.1136/ejhpharm-2018-eahpconf.131
https://doi.org/10.1136/ejhpharm-2018-eahpconf.131